CIP
TRDA icon

Cornerstone Investment Partners’s Entrada Therapeutics TRDA Stock Holding History

Cornerstone Investment Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,943
Closed -$98.9K – 234
2025
Q1 		$98.9K Sell
10,943
-946
-8% -$11.8K ﹤0.01% 186
2024
Q4 		$206K Sell
11,889
-1
-0% -$18 0.01% 195
2024
Q3 		$190K Buy
11,890
+500
+4% +$7.88K 0.01% 182
2024
Q2 		$162K Buy
+11,390
New +$162K 0.01% 187

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Cornerstone Investment Partners's TRDA Position: Q2 2025 in Review

Cornerstone Investment Partners sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 10,943 shares — an estimated $98.9K sold.

Cornerstone Investment Partners first reported a position in TRDA in Q2 2024 and held it in 4 quarters. The position peaked at $206K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Cornerstone Investment Partners reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cornerstone Investment Partners sold 10,943 Entrada Therapeutics shares in Q2 2025, an estimated $98.9K.
  • Cornerstone Investment Partners first reported a position in Entrada Therapeutics in Q2 2024 and held it in 4 quarters.
  • Cornerstone Investment Partners's Entrada Therapeutics position peaked at $206K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Cornerstone Investment Partners's 13F filing for Q2 2025, filed 6 Aug 2025.